# Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

> **NCT06592833** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 60 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Pimavanserin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06592833
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592833, "Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06592833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*